Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis

被引:61
|
作者
Kondoh, Yasuhiro [1 ]
Cottin, Vincent [2 ]
Brown, Kevin K. [3 ]
机构
[1] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Japan
[2] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Dept Resp Med, Natl Reference Ctr Rare Pulm Dis, Lyon, France
[3] Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA
来源
EUROPEAN RESPIRATORY REVIEW | 2017年 / 26卷 / 145期
关键词
IMMOBILIZED FIBER COLUMN; EXTRACORPOREAL MEMBRANE-OXYGENATION; PLACEBO-CONTROLLED TRIAL; INTERSTITIAL PNEUMONIA; MECHANICAL VENTILATION; RESPIRATORY-FAILURE; NONINVASIVE VENTILATION; ANTICOAGULANT-THERAPY; LUNG TRANSPLANTATION; COMPUTED-TOMOGRAPHY;
D O I
10.1183/16000617.0050-2017
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Recognising recent advances, the definition and diagnostic criteria for acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) have been updated by an international working group. The new definition describes any acute, clinically significant respiratory deterioration (both idiopathic and triggered events) characterised by evidence of new widespread alveolar abnormality. The new criteria require a previous or concurrent diagnosis of IPF, an acute worsening or development of dyspnoea typically less than 1 month in duration, chest imaging evidence on computed tomography (CT) of new bilateral ground-glass opacity and/or consolidation superimposed on a background imaging pattern of usual interstitial pneumonia not fully explained by cardiac failure or fluid overload. Due to high in-hospital mortality rates, current treatment guidelines say that the majority of patients with AE-IPF should not receive mechanical ventilation. However, new data suggest that the prognosis may have improved. This modest improvement in overall survival seen in more recent studies may be the result of differences in the diagnostic criteria, study design, baseline clinical risk factors and/or improvements in management. Based on our updated knowledge of possible preventive and therapeutic measures, including mechanical ventilation and pharmacological therapies, the current approach to the treatment of AE-IPF requires careful decision-making.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Update on therapeutic management of idiopathic pulmonary fibrosis
    Tzouvelekis, Argyris
    Bonella, Francesco
    Spagnolo, Paolo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 359 - 370
  • [22] Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis
    Zhuang, Yi
    Zhou, Ying
    Qiu, Xiaohua
    Xiao, Yonglong
    Cai, Hourong
    Dai, Jinghong
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] CORTICOSTEROID AND CYCLOPHOSPHAMIDE IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS: A SINGLE CENTER EXPERIENCE AND LITERATURE REVIEW
    Novelli, Luca
    Ruggiero, Roberto
    De Giacomi, Federica
    Biffi, Alice
    Faverio, Paola
    Bilucaglia, Luca
    Gamberini, Silvia
    Messinesi, Grazia
    Pesci, Alberto
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2016, 33 (04) : 385 - 391
  • [24] Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
    Kodai Kawamura
    Kazuya Ichikado
    Yuko Yasuda
    Keisuke Anan
    Moritaka Suga
    BMC Pulmonary Medicine, 17
  • [25] Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
    Kawamura, Kodai
    Ichikado, Kazuya
    Yasuda, Yuko
    Anan, Keisuke
    Suga, Moritaka
    BMC PULMONARY MEDICINE, 2017, 17 : 23 - 30
  • [26] Viruses in Idiopathic Pulmonary Fibrosis Etiology and Exacerbation
    Moore, Bethany B.
    Moore, Thomas A.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 : S186 - S192
  • [27] Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments
    Luo, Xiaohui
    Xiang, Fei
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4727 - 4741
  • [28] Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: Comparison with idiopathic pulmonary fibrosis
    Otsuka, Junji
    Yoshizawa, Shigeru
    Kudo, Kunihiro
    Osoreda, Hisayuki
    Ishimatsu, Akiko
    Taguchi, Kazuhito
    Moriwaki, Atsushi
    Wakamatsu, Kentaro
    Iwanaga, Tomoaki
    Yoshida, Makoto
    RESPIRATORY MEDICINE, 2022, 200
  • [29] Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis
    Enomoto, Noriyuki
    Oyama, Yoshiyuki
    Yasui, Hideki
    Karayama, Masato
    Hozumi, Hironao
    Suzuki, Yuzo
    Kono, Masato
    Furuhashi, Kazuki
    Fujisawa, Tomoyuki
    Inui, Naoki
    Nakamura, Yutaro
    Suda, Takafumi
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [30] Prognosis of acute exacerbation in idiopathic pulmonary fibrosis with pulmonary emphysema: a retrospective cohort study in Japan
    Horio, Yukihiro
    Takihara, Takahisa
    Takahashi, Fuminari
    Enokida, Keito
    Nakamura, Noriko
    Tanaka, Jun
    Tomomatsu, Katsuyoshi
    Niimi, Kyoko
    Tajiri, Sakurako
    Hayama, Naoki
    Ito, Yoko
    Oguma, Tsuyoshi
    Asano, Koichiro
    BMJ OPEN, 2022, 12 (09):